UK markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
34.67-1.76 (-4.83%)
At close: 04:00PM EDT
34.67 0.00 (0.00%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.40B
Enterprise value 1.58B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)308.16
Price/book (mrq)2.86
Enterprise value/revenue 260.11
Enterprise value/EBITDA -17.34

Trading information

Stock price history

Beta (5Y monthly) 1.47
52-week change 32.10%
S&P500 52-week change 323.23%
52-week high 353.18
52-week low 322.11
50-day moving average 337.91
200-day moving average 335.04

Share statistics

Avg vol (3-month) 3672.92k
Avg vol (10-day) 3669.75k
Shares outstanding 565.91M
Implied shares outstanding 665.91M
Float 865.74M
% held by insiders 10.26%
% held by institutions 1107.45%
Shares short (15 May 2024) 46.62M
Short ratio (15 May 2024) 411.38
Short % of float (15 May 2024) 411.62%
Short % of shares outstanding (15 May 2024) 410.04%
Shares short (prior month 15 Apr 2024) 46.75M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 311 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-26,030.77%

Management effectiveness

Return on assets (ttm)-15.73%
Return on equity (ttm)-25.39%

Income statement

Revenue (ttm)6.07M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)-83.90%
Gross profit (ttm)N/A
EBITDA -147.12M
Net income avi to common (ttm)-144.88M
Diluted EPS (ttm)-2.86
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)823.85M
Total cash per share (mrq)12.5
Total debt (mrq)2.11M
Total debt/equity (mrq)0.25%
Current ratio (mrq)31.77
Book value per share (mrq)12.72

Cash flow statement

Operating cash flow (ttm)-119.36M
Levered free cash flow (ttm)-54.98M